Pyxis Oncology’s (PYXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report published on Thursday,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

Several other brokerages have also weighed in on PYXS. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday. Stephens began coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.90 on Thursday. The company has a 50 day simple moving average of $3.64 and a 200-day simple moving average of $3.61. The firm has a market capitalization of $112.99 million, a price-to-earnings ratio of -1.84 and a beta of 1.27. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently modified their holdings of the company. Ikarian Capital LLC bought a new position in shares of Pyxis Oncology in the first quarter valued at approximately $7,082,000. Vanguard Group Inc. grew its stake in shares of Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after acquiring an additional 94,740 shares during the last quarter. Millennium Management LLC grew its stake in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after acquiring an additional 57,016 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Pyxis Oncology in the second quarter worth $3,462,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.